U.S. Food and Drug Administration (FDA) · United States
FDA Non-Compliant Medical Software Marketing
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.
21 U.S.C. 321(h), 352(a), 360j(o)(1)
What is FDA Non-Compliant Medical Software Marketing?
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians. Apply to US app store listings, websites, social and digital ads for health, medical and AI clinical software.
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.
How can marketing teams comply?
Apply to US app store listings, websites, social and digital ads for health, medical and AI clinical software.
What is FDA Non-Compliant Medical Software Marketing?
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.